<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5041">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03041311</url>
  </required_header>
  <id_info>
    <org_study_id>G1T28-05</org_study_id>
    <secondary_id>2017-000358-20</secondary_id>
    <nct_id>NCT03041311</nct_id>
  </id_info>
  <brief_title>Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)</brief_title>
  <official_title>Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G1 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in
      preserving the bone marrow and the immune system, and enhancing antitumor efficacy when
      administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line
      treatment for patients with newly diagnosed extensive-stage SCLC.

      The study is a randomized, double-blinded, placebo-controlled design. The study will include
      3 study phases: Screening Phase,Treatment Phase (induction part + maintenance part), and
      Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study
      treatment and completes at the Post-Treatment Visit. Approximately, 100 patients will be
      enrolled in the study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related adverse events (AE) based on NCI CTCAE v4.0</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with objective response (CR or PR) based on RECIST v1.1</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS based on RECIST v1.1</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Laboratory Events</measure>
    <time_frame>24 Months</time_frame>
    <description>Incidence of Grade 3 and 4 abnormalities in safety-related laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of of immune-related adverse events (irAEs)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>trilaciclib+etoposide/carboplatin/atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Patients will receive trilaciclib 240 mg/m2 administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.
Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+etoposide/carboplatin/atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Patients will receive placebo administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.
Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trilaciclib</intervention_name>
    <description>Trilaciclib IV</description>
    <arm_group_label>trilaciclib+etoposide/carboplatin/atezolizumab</arm_group_label>
    <other_name>G1T28</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV</description>
    <arm_group_label>placebo+etoposide/carboplatin/atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin IV</description>
    <arm_group_label>trilaciclib+etoposide/carboplatin/atezolizumab</arm_group_label>
    <arm_group_label>placebo+etoposide/carboplatin/atezolizumab</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide IV</description>
    <arm_group_label>trilaciclib+etoposide/carboplatin/atezolizumab</arm_group_label>
    <arm_group_label>placebo+etoposide/carboplatin/atezolizumab</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab IV</description>
    <arm_group_label>trilaciclib+etoposide/carboplatin/atezolizumab</arm_group_label>
    <arm_group_label>placebo+etoposide/carboplatin/atezolizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged â‰¥18 years

          -  Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably
             including the presence of neuroendocrine features by immunohistochemistry

          -  At least 1 target lesion that is measurable by RECIST, Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior chemotherapy for extensive-stage SCLC

          -  Prior immunotherapies including but not limited to CD137, anti-PD-1, anti-PD-L1, and
             CTLA4.

          -  Presence of symptomatic brain metastases requiring immediate treatment with radiation
             therapy or steroids.

          -  History of pulmonary fibrosis, organizing pneumonia or pneumonitis on screening chest
             CT

          -  Active, known, suspected autoimmune disease requiring systemic treatment in the past
             2 years

          -  Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart
             failure

          -  Known history of stroke or cerebrovascular accident within 6 months prior to
             enrollment

          -  Other uncontrolled serious chronic disease or conditions that in the investigator's
             opinion could affect compliance or follow-up in the protocol

          -  Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to
             enrollment

          -  Receipt of any investigational medication within 4 weeks prior to enrollment

          -  Administration of attenuated vaccine within 4 weeks before enrollment

          -  Systemic treatment with corticosteriods or other immunosuppressive medications within
             14 days of study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Contact</last_name>
    <role>Study Director</role>
    <affiliation>G1 Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G1Therapeutics Clinical Contact</last_name>
    <email>clinicalinfo@g1therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Medical Center - Santa Monica Hematology And Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jonathan Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Trevor Feinstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital - Georgia Cancer Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Steven McCune, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jason Suh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Center</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Wael A. Harb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Westchester Hospital</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jonathan Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Belvoir Community Hospital</name>
      <address>
        <city>Fort Belvoir</city>
        <state>Virginia</state>
        <zip>22060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pramvir S. Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>February 1, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>CDK 4/6 Inhibitor</keyword>
  <keyword>Immune Checkpoint Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
